AOH1996 for the Treatment of Refractory Solid Tumors

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
City of Hope Medical Center
Study ID
NCT05227326
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • PCNA Inhibitor AOH1996 — DRUG
    Given PO

Study Details

This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory). AOH1996 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Key Dates

Start date
Aug 12, 2022
Status verified
Sep 2025
Primary completion
Sep 13, 2029
Completion
Sep 13, 2029

Study Design

Enrollment
92 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (PCNA inhibitor AOH1996)
    Patients receive PCNA inhibitor AOH1996 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Incidence of adverse events (AEs) [ Time Frame: Up to 30 days after last study drug is given ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Honor Health Research and Innovation InstituteScottsdaleArizona85258
Patient Services
[email protected]
800-826-4673
Erkut Borazanci, MD (PRINCIPAL_INVESTIGATOR)
City of Hope Medical CenterDuarteCalifornia91010
Patient Services
[email protected]
800-826-4673
Vincent Chung, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Scottsdale, AZ

By condition
Lung cancerOvarian cancerPancreatic cancer
By specialty
OncologyLung oncologyLung diseaseGynecologic oncologyWomen's healthGI oncology
By research site
Honor Health Research and Innovation Institute· Scottsdale, AZCity of Hope Medical Center· Duarte, CA

Related Studies